Welcome to our dedicated page for cbdMD news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on cbdMD stock.
cbdMD, Inc. (NYSE American: YCBD) is a premier provider of high-quality, hemp-derived cannabidiol (CBD) products. Founded in 2015 and headquartered in Charlotte, North Carolina, cbdMD has quickly become one of the most highly trusted and recognized names in the CBD industry. The company offers a broad range of CBD products under its flagship brand cbdMD, as well as its pet-focused brand Paw CBD and its newly launched ATRx Labs line of functional mushroom supplements.
The company's product portfolio includes CBD tinctures, gummies, topicals, capsules, bath bombs, bath salts, sleep aids, and veterinarian-formulated pet CBD products like tinctures, chews, and topicals. It has built a robust distribution network, leveraging its own e-commerce platform, third-party online marketplaces, wholesalers, and a variety of brick-and-mortar retailers across the United States.
In recent developments, cbdMD has introduced innovative products such as the THCV+CBG Energy Softgels, which combine the potency of two dynamic cannabinoids with caffeine and B12 to enhance energy, focus, and clarity. The company's dedication to innovation is also evident in the launch of its CBD+CBG Oil Tincture and the introduction of a new Vice President of Wholesale Sales to expand its market reach.
Financially, cbdMD has been proactive in securing funding to support its growth. Recently, the company entered a securities purchase agreement, raising $1.25 million in gross proceeds to bolster working capital and support the national rollout of its ATRx Labs functional mushroom products. Despite reporting operational losses, cbdMD has implemented cost-cutting measures and strategic initiatives aimed at achieving profitability and enhancing shareholder value.
cbdMD's latest product,
cbdMD, Inc. (NYSE American: YCBD) has attained the U.S. Hemp Authority™ Certification, demonstrating its commitment to high-quality CBD products. This prestigious certification, awarded after a comprehensive third-party audit by Food Chain ID, allows cbdMD to use the Certified Seal on its product packaging, reinforcing its adherence to ISO and cGMP standards. The certification complements its NSF GMP registration, assuring consumers of the quality and safety of cbdMD's hemp-derived products. The company emphasizes its dual commitment to testing and quality management in providing trusted CBD solutions.
cbdMD, Inc. (NYSE American: YCBD) has entered an exclusive sponsorship as the Official CBD Partner of the NOBULL CrossFit Games, scheduled for July 27 - August 1 in Madison, Wisconsin. Additionally, it will sponsor the NOBULL CrossFit Games Semifinals from May 28 to June 20. This partnership connects cbdMD with an audience of 11 million viewers and over 14,000 affiliated gyms worldwide. cbdMD aims to integrate its brand with the CrossFit community, emphasizing its products' role in athlete recovery.
cbdMD, Inc. (NYSE American: YCBD) will host a conference call on May 12, 2021, at 4:15 p.m. ET to discuss its second quarter financial results for the period ending March 31, 2021. Interested participants can join the call by dialing 1-888-506-0062 domestically or 1-973-528-0011 internationally. A replay will be available through June 11, 2021, with a passcode of 41216. Details for accessing the webcast and replay are also provided in the announcement.
cbdMD, a prominent provider of CBD products, has appointed Dr. Sibyl Swift as Vice President for Scientific & Regulatory Affairs, after her prior role as a regulatory consultant. Dr. Swift previously held significant roles at the FDA and the Natural Products Association, enhancing cbdMD's commitment to quality and safety. She will oversee GMP compliance and product quality initiatives, including guiding Novel Food Applications with UK and European authorities. The Company's extensive range includes over 130 CBD SKUs, emphasizing its market position and regulatory focus.
cbdMD (NYSE American: YCBD) announced the filing of its Novel Food Application with the UK’s Food Standards Agency on March 26. The application includes comprehensive data for validation and scientific assessment, with a similar submission made to the European Food Safety Authority. The review process is expected to conclude by the end of 2021, although no assurance of approval can be guaranteed. This step is crucial for cbdMD's future regulatory submissions globally, potentially impacting their market presence.
cbdMD, Inc. (NYSE American: YCBD) recently announced a Spring 2021 product launch featuring new product lines, including an extension of their award-winning Gummies and the introduction of the highly anticipated Drink Mixes. The Gummies will include Sleep Gummies, Calming Gummies, and Apple Cider Vinegar Gummies in various strengths, priced from $29.95 to $89.95. The Drink Mixes, infused with 25MG of CBD, will be available in several flavors and will be priced between $29.95 and $69.95. This innovation reinforces cbdMD's commitment to quality and product development in the CBD market.
cbdMD, Inc. (NYSE American: YCBD) has entered an exclusive sponsorship agreement with 9-time PGA TOUR winner Patrick Reed, starting with the 2021 Masters Tournament. Reed, currently ranked 7th globally, will showcase the cbdMD logo on his headwear during PGA and European Tour events. This partnership aims to enhance cbdMD's brand visibility through additional marketing opportunities. Patrick Reed expressed enthusiasm for joining the cbdMD team, citing his positive experiences with their products. cbdMD continues to strengthen its position as a leading CBD brand.
Adara Acquisition Corp. (NYSE American: ADRA.U) announced that from March 24, 2021, holders of its 11,500,000 IPO units can trade shares of Class A common stock and warrants separately on NYSE American under the symbols 'ADRA' and 'ADRA WS'. No fractional warrants will be issued. Units not separated will continue trading under 'ADRA.U'. The registration statement was effective as of February 8, 2021. The Company aims to pursue mergers or acquisitions, particularly in the consumer products sector. ThinkEquity acted as the sole book-running manager for the offering.
cbdMD, Inc. (NYSE American: YCBD) has established cbdMD Therapeutics LLC, a wholly-owned subsidiary aimed at advancing scientific research around CBD and its therapeutic applications. Dr. Sibyl Swift and Lance Blundell will co-chair this initiative, focusing on developing novel therapies for pain, inflammation, and anxiety disorders. The company aims to replace opioid use with cannabinoid-based solutions. The market confirms a growing interest in cannabinoid medicines, highlighted by Jazz Pharmaceuticals' recent $7.2 billion acquisition of GW Pharmaceuticals.
cbdMD, Inc. (NYSE American: YCBD) has announced that a California class action lawsuit against the company is temporarily stayed. This ruling comes as the judge responded to cbdMD's motion while awaiting the U.S. Food and Drug Administration's guidelines or potential legislation regarding CBD product definitions and marketing. The lawsuit, filed in December 2019, accused cbdMD and others of violating several California laws. The stay closes the case administratively, with parties required to submit status updates every 90 days, starting June 2021.
FAQ
What is the current stock price of cbdMD (YCBD)?
What is the market cap of cbdMD (YCBD)?
What does cbdMD, Inc. specialize in?
What are cbdMD's latest product innovations?
How does cbdMD distribute its products?
What recent financial steps has cbdMD taken?
What is the significance of cbdMD's ATRx Labs line?
Is cbdMD financially stable?
What challenges is cbdMD currently facing?
Where is cbdMD headquartered?
Who recently joined the cbdMD team?
What are cbdMD's future plans?
